Literature DB >> 8608410

In vitro tolerability of human nasal mucosa: histopathological and scanning electron-microscopic evaluation of nasal forms containing Sandostatin.

A de Fraissinette1, M Kolopp, I Schiller, G Fricker, C Gammert, A Pospischil, J Vonderscher, F Richter.   

Abstract

An in vitro human nasal model was developed as a tool to study the local tolerability of nasal powder forms using excised nasal mucosa in a diffusion chamber. The suitability of this model was tested using Sandostatin (SMS) an octapeptide analog of somatostatin, as a reference drug enhanced by Avicel (microcrystalline cellulose) or lactose (100 mesh). The standard nasal spray vehicle was taken as a harmless control and 1% chenodeoxycholate (CDC) as a harmful control in terms of local tolerability. The extent of peptide permeation was determined by measuring SMS concentration in the receiving chamber. The labeling of SMS was detected by immunoperoxidase staining on cross sections. The local tolerability for all tested forms was assessed by histopathological examination and scanning electron microscopy. The apparent permeation coefficient allowed us to rank the absorption of the tested drug forms as Avicel > spray = lactose > 1%CDC. For all formulations, SMS was detected in the epithelium. No changes of the nasal mucosa could be observed with Avicel, lactose or nasal spray vehicle in the presence or absence of SMS. 1%CDC with or without drug showed an immediate destruction of the nasal epithelium. The validation of this in vitro model using human nasal mucosa will be further discussed as a tool for assessing the local tolerability of intranasally applied test substances.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608410     DOI: 10.1007/bf00757627

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  12 in total

1.  The molecular weight dependence of nasal absorption: the effect of absorption enhancers.

Authors:  M D Donovan; G L Flynn; G L Amidon
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 2.  The use of cultured epithelial and endothelial cells for drug transport and metabolism studies.

Authors:  K L Audus; R L Bartel; I J Hidalgo; R T Borchardt
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Nasal delivery of polypeptides I: nasal absorption of enkephalins in rats.

Authors:  K S Su; K M Campanale; L G Mendelsohn; G A Kerchner; C L Gries
Journal:  J Pharm Sci       Date:  1985-04       Impact factor: 3.534

4.  Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization.

Authors:  G Fricker; C Bruns; J Munzer; U Briner; R Albert; T Kissel; J Vonderscher
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

5.  A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.

Authors:  J Weeke; S E Christensen; H Orskov; A Kaal; M M Pedersen; P Illum; A G Harris
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

6.  Treatment of external biliary, pancreatic and intestinal fistulas with a somatostatin analog.

Authors:  S Kocak; C Bumin; K Karayalcin; I Alacayir; D Aribal
Journal:  Dig Dis       Date:  1994 Jan-Feb       Impact factor: 2.404

7.  Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol.

Authors:  W C Shyu; R F Mayol; M Pfeffer; K A Pittman; R E Gammans; R H Barbhaiya
Journal:  Biopharm Drug Dispos       Date:  1993-07       Impact factor: 1.627

8.  Influence of degradable starch microspheres on the human nasal mucosa.

Authors:  K Holmberg; E Björk; B Bake; P Edman
Journal:  Rhinology       Date:  1994-06       Impact factor: 3.681

9.  Preliminary results with Sandostatin nasal powder in acromegalic patients.

Authors:  A G Harris; J Weeke; S E Christensen; A Kaal; P Illum; H Orskov
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

10.  Octreotide treatment of acromegaly. A randomized, multicenter study.

Authors:  S Ezzat; P J Snyder; W F Young; L D Boyajy; C Newman; A Klibanski; M E Molitch; A E Boyd; L Sheeler; D M Cook
Journal:  Ann Intern Med       Date:  1992-11-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.